Manchester Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Manchester Capital Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-550	Closed	-$21K	–	564
2016 Q1	$21K	Hold	550	–	–	﹤0.01%	494
2015 Q4	$28K	Hold	550	–	–	﹤0.01%	534
2015 Q3	$25K	Hold	550	–	–	﹤0.01%	521
2015 Q2	$32K	Hold	550	–	–	0.01%	440
2015 Q1	$30K	Hold	550	–	–	﹤0.01%	426
2014 Q4	$28K	Hold	550	–	–	﹤0.01%	834
2014 Q3	$25K	Hold	550	–	–	﹤0.01%	850
2014 Q2	$24K	Hold	550	–	–	﹤0.01%	837
2014 Q1	$23K	Buy	+550	New	+$23.5K	﹤0.01%	748

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Manchester Capital Management's PBE Position: Q2 2016 in Review

Manchester Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2016, closing a stake of 550 shares — an estimated $21K sold.

Manchester Capital Management first reported a position in PBE in Q1 2014 and held it in 9 quarters. The position peaked at $32K in Q2 2015. 73 funds tracked by Wall St. Rank hold PBE as of Q2 2016.

Manchester Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2016 after selling out during the quarter.
Manchester Capital Management sold 550 Invesco Biotechnology & Genome ETF shares in Q2 2016, an estimated $21K.
Manchester Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and held it in 9 quarters.
Manchester Capital Management's Invesco Biotechnology & Genome ETF position peaked at $32K in Q2 2015.
73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2016.

Based on Manchester Capital Management's 13F filing for Q2 2016, filed 20 Jul 2016.